Non-Cystic Fibrosis Bronchiectasis Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 12+ Leading Players Wheeling the Therapeutics Landscape

(Albany, US) September 17, 2026 – DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis Pipeline Insights 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in the Non-Cystic Fibrosis Bronchiectasis Pipeline landscape. It covers the Non-Cystic Fibrosis Bronchiectasis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Non-Cystic Fibrosis Bronchiectasis research @ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

• In September, 2026, UCB Biopharma SRL initiated a phase 2 study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB).
• In September 2026 – Insmed continued advancing Brinsupri (brensocatib), its DPP1 inhibitor approved for Non-Cystic Fibrosis Bronchiectasis, as the therapy remains an important targeted treatment option for reducing exacerbations associated with the chronic respiratory disease.
• DelveInsight’s Non-Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Non-Cystic Fibrosis Bronchiectasis treatment.
• The leading Non-Cystic Fibrosis Bronchiectasis Companies include Haisco Pharmaceutical Group Co., Ltd., CSL Limited, UCB S.A., S-INFINITY Pharmaceuticals Co., Ltd, Reistone Biopharma Company Limited, and others.
• Promising Non-Cystic Fibrosis Bronchiectasis Therapies such as HSK31858, Galvokimig, CSL787, Brensocatib 10 mg, Ciprofloxacin for Inhalation, RESP302, BAY85-8501, Itepekimab (SAR440340), and others.

Download for updates and be a part of the revolution in cancer care @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials Assessment

The Non-Cystic Fibrosis Bronchiectasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Non-Cystic Fibrosis Bronchiectasis Pipeline Report also highlights the unmet needs with respect to the Non-Cystic Fibrosis Bronchiectasis.

Non-Cystic Fibrosis Bronchiectasis Overview

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive lung disease defined by permanent, abnormal dilation of the bronchi, leading to impaired mucociliary transport, chronic airway infection, and inflammation. Unlike cystic fibrosis, NCFB is a heterogeneous condition often resulting from various infectious or inflammatory causes, rather than a single genetic mutation. It can occur due to various factors, including pneumonia, abnormalities of cilia, and immune deficiencies. It most frequently affects the elderly. Patients suffering from NCFB generally experience increased morbidity and worse quality of life. NCFB is characterized by symptoms that often develop gradually over months or years and tend to worsen over time. The hallmark features include a persistent daily cough and chronic production of mucus. Patients may also experience chest pain, shortness of breath, and wheezing during breathing. Additional symptoms can include fatigue, recurrent fevers or chills, and in some cases coughing up blood or blood-streaked mucus (hemoptysis). As the disease progresses, physical signs such as clubbing thickening of the skin under the fingernails and toenails may also occur, reflecting chronic respiratory impairment.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

• HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 is a novel, oral, irreversible dipeptidyl peptidase-1 (DPP-1) inhibitor being developed by Haisco Pharmaceutical for treating neutrophil-mediated chronic inflammatory diseases, particularly non-cystic fibrosis bronchiectasis. It aims to reduce neutrophil-driven inflammation and exacerbations. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

• CSL787: CSL Behring

CSL787 is a novel, nebulized 10% human plasma-derived polyvalent immunoglobulin G (IgG) solution being developed by CSL Behring to treat chronic lung infections, specifically in non-cystic fibrosis bronchiectasis (NCFB) patients. It uses a customized vibrating-mesh nebulizer for targeted, non-invasive delivery to the airways. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

• Galvokimig: UCB S.A.

Galvokimig is a multispecific antibody based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

Learn more about Non-Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking research and development projects @ Non-Cystic Fibrosis Bronchiectasis Unmet Needs

The Non-Cystic Fibrosis Bronchiectasis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
• Non-Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Cystic Fibrosis Bronchiectasis Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.

Non-Cystic Fibrosis Bronchiectasis Companies

Haisco Pharmaceutical Group Co., Ltd., CSL Limited, UCB S.A., S-INFINITY Pharmaceuticals Co., Ltd, Reistone Biopharma Company Limited, and others.

The Non-Cystic Fibrosis Bronchiectasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we’re transforming the future of oncology @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives

Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

• Coverage- Global
• Non-Cystic Fibrosis Bronchiectasis Companies- Haisco Pharmaceutical Group Co., Ltd., CSL Limited, UCB S.A., S-INFINITY Pharmaceuticals Co., Ltd, Reistone Biopharma Company Limited, and others.
• Non-Cystic Fibrosis Bronchiectasis Therapies– HSK31858, Galvokimig, CSL787, Brensocatib 10 mg, Ciprofloxacin for Inhalation, RESP302, BAY85-8501, Itepekimab (SAR440340) and others.
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of the Non-Cystic Fibrosis Bronchiectasis Pipeline on our website, @ Non-Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. HSK31858: Haisco Pharmaceutical Group Co., Ltd.
8. Comparative Analysis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CSL787: CSL Behring
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. MM-120: Mind Medicine
15. Inactive Products
16. Non-Cystic Fibrosis Bronchiectasis Key Companies
17. Non-Cystic Fibrosis Bronchiectasis Key Products
18. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
19. Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
20. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion
21. Non-Cystic Fibrosis Bronchiectasis Analyst Views
22. Non-Cystic Fibrosis Bronchiectasis Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight